BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18583418)

  • 1. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
    Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B
    Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
    Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
    Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.
    Portella G; Borselli C; Santoro M; Gerbasio D; D'Armiento MR; Dumont JE; Ledent C; Rothstein JL; Vecchio G; Fusco A
    Oncol Res; 2001; 12(8):347-54. PubMed ID: 11589306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland.
    Prost G; Bernier-Valentin F; Croset M; Rousset B
    Endocr Relat Cancer; 2009 Sep; 16(3):873-84. PubMed ID: 19509066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
    Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
    Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene.
    Coppée F; Gérard AC; Denef JF; Ledent C; Vassart G; Dumont JE; Parmentier M
    Oncogene; 1996 Oct; 13(7):1471-82. PubMed ID: 8875985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological changes induced by selective inactivation of menin on the thyroid gland in RET÷PTC3 and E7 transgenic mice. A study of 77 cases.
    Căpraru OM; Berger N; Gadot N; Decaussin-Petrucci M; Zhang C; Borda A; Szilágyi T; Borson-Chazot F; Selmi-Ruby S
    Rom J Morphol Embryol; 2016; 57(1):91-8. PubMed ID: 27151693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.
    Shinohara S; Rothstein JL
    Oncogene; 2004 Sep; 23(45):7571-9. PubMed ID: 15326486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.
    Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L
    PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
    Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
    J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation induced thyroid cancer: fundamental and applied aspects.
    Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
    Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
    Nakazawa T; Kondo T; Kobayashi Y; Takamura N; Murata S; Kameyama K; Muramatsu A; Ito K; Kobayashi M; Katoh R
    Cancer; 2005 Sep; 104(5):943-51. PubMed ID: 16015630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.
    Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA
    Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
    Basolo F; Giannini R; Monaco C; Melillo RM; Carlomagno F; Pancrazi M; Salvatore G; Chiappetta G; Pacini F; Elisei R; Miccoli P; Pinchera A; Fusco A; Santoro M
    Am J Pathol; 2002 Jan; 160(1):247-54. PubMed ID: 11786418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
    Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.